Video

Ahuno on Bringing Precision Medicine in Cancer Care to Ghana

Author(s):

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

Samuel Ahuno, a visiting masters student and collaborator at Mount Sinai from Kwame Nkrumah University of Science and Technology (KNUST), Ghana, discusses bringing precision medicine in cancer care to Ghana.

The prospect of utilizing circulating tumor DNA (ctDNA) to detect and study cancer through readily available means is exciting, according to Ahuno, who is conducting genomic research in Ghana under the supervision of Paz Polak, PhD, of Mount Sinai. Although their research has just begun, it may be beneficial to expand to larger prospective studies that will utilize ctDNA samples and validate current findings regarding cancer genomes in Ghana; it may also be beneficial to expand this effort to other African countries, Ahuno says.

Additionally, it will be important to collaborate with clinicians in Ghana to begin utilizing ctDNA testing before it can be implemented at institutions there, Ahuno says. The aforementioned genomic research has helped to lay the foundation for precision medicine in Ghana with the possibility of bringing precision medicine in cancer care to other African countries through collaboration with Ghanian institutes and scientists, Ahuno concludes. 

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Marc Machaalani, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO